1. Home
  2. EFSI vs XGN Comparison

EFSI vs XGN Comparison

Compare EFSI & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Financial Services Inc

EFSI

Eagle Financial Services Inc

N/A

Current Price

$39.73

Market Cap

214.3M

Sector

Finance

ML Signal

N/A

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$7.13

Market Cap

253.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EFSI
XGN
Founded
1881
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
214.3M
253.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EFSI
XGN
Price
$39.73
$7.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$39.50
$13.67
AVG Volume (30 Days)
13.6K
303.7K
Earning Date
10-23-2025
11-04-2025
Dividend Yield
3.14%
N/A
EPS Growth
N/A
N/A
EPS
2.13
N/A
Revenue
$66,122,000.00
$63,599,000.00
Revenue This Year
N/A
$22.15
Revenue Next Year
$27.28
$15.26
P/E Ratio
$18.53
N/A
Revenue Growth
3.18
14.08
52 Week Low
$28.70
$2.67
52 Week High
$40.38
$12.23

Technical Indicators

Market Signals
Indicator
EFSI
XGN
Relative Strength Index (RSI) 70.14 30.11
Support Level $37.76 $7.01
Resistance Level $40.38 $7.33
Average True Range (ATR) 0.76 0.32
MACD 0.31 0.07
Stochastic Oscillator 82.57 18.09

Price Performance

Historical Comparison
EFSI
XGN

About EFSI Eagle Financial Services Inc

Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: